Pfizer, BioNTech Ask FDA to Approve Booster for Children

Dow Jones2022-09-26

Pfizer Inc. and German partner BioNTech SE said Monday they have submitted an application to the U.S. Food and Drug Administration seeking an emergency use authorization for their bivalent vaccine booster for use in children aged 5 to 11 years of age.

The application is for a 10-ug booster dose of the vaccine targeting omicron BA.4 and BA.5 subvariants, which have become dominant in the U.S and around the world. The application "is supported by safety and immunogenicity data from the companies' Omicron BA.1-adapted bivalent vaccine, non-clinical and manufacturing data from the companies' 10-ug Omicron BA.4/BA.5-adapted bivalent vaccine, and preclinical data from the companies' Omicron BA.4/BA.5-adapted bivalent vaccine," the companies said in a joint statement.

An application for the same age group will be submitted to the European Union regulator in the coming days. The companies have also started a Phase 1/2/3 study to evaluate different doses and dosings of the same vaccine for use in children aged six months through 11 years old. Pfizer shares were down 0.9% premarket while BioNTech was down 0.8%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Jess321
2022-09-26
Jess321
Ok
stsockli
2022-09-26
stsockli
👍

Leave a comment

2

57

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2270235503?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-26 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2270235503","market":"us","top_or_hot":-1,"title":"Pfizer, BioNTech Ask FDA to Approve Booster for Children","media":"Dow Jones","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer Inc.</a> and German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> said Monday they have submitted an application to the U.S. Food and Drug Administration seeking an emergency use authorization for their bivalent vaccine booster for use in children aged 5 to 11 years of age.</p><p>The application is for a 10-ug booster dose of the vaccine targeting omicron BA.4 and BA.5 subvariants, which have become dominant in the U.S and around the world. The application &#34;is supported by safety and immunogenicity data from the companies&#39; Omicron BA.1-adapted bivalent vaccine, non-clinical and manufacturing data from the companies&#39; 10-ug Omicron BA.4/BA.5-adapted bivalent vaccine, and preclinical data from the companies&#39; Omicron BA.4/BA.5-adapted bivalent vaccine,&#34; the companies said in a joint statement.</p><p>An application for the same age group will be submitted to the European Union regulator in the coming days. The companies have also started a Phase 1/2/3 study to evaluate different doses and dosings of the same vaccine for use in children aged six months through 11 years old. Pfizer shares were down 0.9% premarket while BioNTech was down 0.8%.</p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech Ask FDA to Approve Booster for Children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech Ask FDA to Approve Booster for Children\n</h2>\n\n<h4 class=\"meta\">\n\n2022-09-26 19:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Dow Jones</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. and German partner BioNTech SE said Monday they have submitted an application to the U.S. Food and Drug Administration seeking an emergency use authorization for their bivalent vaccine ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"","article_id":"2270235503","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2270235503","pubTimestamp":1664190993,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pfizer Inc. and German partner BioNTech SE said Monday they have submitted an application to the U.S","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"translate_title":"辉瑞、生物技术公司要求FDA批准儿童助推器","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"BNTX":0.9},"content_text":"Pfizer Inc. and German partner BioNTech SE said Monday they have submitted an application to the U.S. Food and Drug Administration seeking an emergency use authorization for their bivalent vaccine booster for use in children aged 5 to 11 years of age.The application is for a 10-ug booster dose of the vaccine targeting omicron BA.4 and BA.5 subvariants, which have become dominant in the U.S and around the world. The application \"is supported by safety and immunogenicity data from the companies' Omicron BA.1-adapted bivalent vaccine, non-clinical and manufacturing data from the companies' 10-ug Omicron BA.4/BA.5-adapted bivalent vaccine, and preclinical data from the companies' Omicron BA.4/BA.5-adapted bivalent vaccine,\" the companies said in a joint statement.An application for the same age group will be submitted to the European Union regulator in the coming days. The companies have also started a Phase 1/2/3 study to evaluate different doses and dosings of the same vaccine for use in children aged six months through 11 years old. Pfizer shares were down 0.9% premarket while BioNTech was down 0.8%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9911655984,"gmtCreate":1664200094448,"gmtModify":1676537408457,"author":{"id":"4087638013719750","authorId":"4087638013719750","name":"Jess321","avatar":"https://static.tigerbbs.com/dc86625c205fcfa9eb51b6291af7f62d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087638013719750","authorIdStr":"4087638013719750"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9911655984","repostId":2270235503,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9911619495,"gmtCreate":1664192180418,"gmtModify":1676537406729,"author":{"id":"4100579485105550","authorId":"4100579485105550","name":"stsockli","avatar":"https://static.tigerbbs.com/73ce4d0a742e9a3ecb6f752ba879b550","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"4100579485105550","authorIdStr":"4100579485105550"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9911619495","repostId":2270235503,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":57,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2270235503"}